ImmunityBio, Inc. (IBRX) Misses Q2 EPS by 14c
Tweet
Share
E-mailGet Alerts IBRX Hot Sheet
Join SI Premium – FREE
ImmunityBio, Inc. (NASDAQ: IBRX) reported Q2 EPS of ($0.22), $0.14 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $51.24 million versus the consensus estimate of $47.22 million.
For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Anthropic delays planned IPO from October to November - WSJ
- Honeywell wins $53.9M Navy contract for navigation parts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
